(19)
(11) EP 2 807 191 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.10.2019 Bulletin 2019/42

(45) Mention of the grant of the patent:
10.07.2019 Bulletin 2019/28

(21) Application number: 13702262.0

(22) Date of filing: 25.01.2013
(51) International Patent Classification (IPC): 
C07K 16/24(2006.01)
(86) International application number:
PCT/GB2013/050162
(87) International publication number:
WO 2013/110945 (01.08.2013 Gazette 2013/31)

(54)

METHODS OF TREATING PAIN BY INHIBITION OF VGF ACTIVITY

VERFAHREN ZUR BEHANDLUNG VON SCHMERZEN MITTELS HEMMUNG DER VGF-AKTIVITÄT

MÉTHODES DE TRAITEMENT DE LA DOULEUR PAR LE BIAIS DE L'INHIBITION DE L'ACTIVITÉ DU VGF

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 26.01.2012 GB 201201332

(43) Date of publication of application:
03.12.2014 Bulletin 2014/49

(73) Proprietor: Imperial College Innovations Limited
London SW7 2AZ (GB)

(72) Inventors:
  • OKUSE, Kenji
    London SW7 2AZ (GB)
  • PRISTERA, Alessandro
    London N22 6SU (GB)
  • RICE, Andrew
    London SW10 9NH (GB)

(74) Representative: Sterling IP 
Orion House Bessemer Road
Welwyn Garden City AL7 1HH
Welwyn Garden City AL7 1HH (GB)


(56) References cited: : 
WO-A1-01/07074
 WO-A2-03/016475
   
  • RIZZI R ET AL: "The VGF-derived peptide TLQP-21: A new modulatory peptide for inflammatory pain", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 441, no. 1, 15 August 2008 (2008-08-15), pages 129-133, XP022822351, ISSN: 0304-3940, DOI: 10.1016/J.NEULET.2008.06.018 [retrieved on 2008-06-12]
  • Moss et al.: "Origins, actions and dynamic expression patterns of theneuropeptide VGF in rat peripheral and central sensory neuronesfollowing peripheral nerve injury", Molecular Pain, vol. 4, no. 62 10 December 2008 (2008-12-10), pages 1-12, XP002695039, BioMed Central Retrieved from the Internet: URL:http://www.molecularpain.com/content/p df/1744-8069-4-62.pdf [retrieved on 2013-04-09]
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).